Skip to main content

Table 1 Characteristics of patients at baseline

From: Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

  Array analysis
(n = 15)
qPCR analysis
(n = 18)
Age, years 51 (39-55) 58 (51-69)
Gender, female/male 7/8 14/4
Disease characteristics   
   DAS28 5.6 (4.6-7.0) 5.7 (5.0-6.6)
   C-reactive protein, mg/dL 8 (6-22) 13 (5-44)
   Erythrocyte sedimentation rate 25 (12-41) 32 (16-47)
   ACPA titer, U/mL 100 (15-595) 541 (121-1,805)
   IgM RF titer, U/mL 28 (14-133) 67 (22-182)
   Disease duration, months 77 (29-240) 65 (36-1,992)
   Erosions n = 13 n = 15
Medication   
   Methotrexate dose, mg/week 25 (20-30) 21 (15-25)
   Prednisone n = 2 n = 5
   NSAID n = 7 n = 12
  1. Values are presented as median (interquartile range 25 to 75) unless indicated otherwise. ACPA, anti-citrullinated protein antibodies; DAS28, disease activity score using 28 joint counts; NSAID, nonsteroidal anti-inflammatory drug; qPCR, quantitative polymerase chain reaction; RF, rheumatoid factor.